相似文献
1
A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma.
Vaccines (Basel). 2021 Aug 18;9(8):919. doi: 10.3390/vaccines9080919.
2
IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time.
Semin Oncol. 2022 Oct;49(5):394-399. doi: 10.1053/j.seminoncol.2022.10.001. Epub 2022 Oct 23.
3
Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Eur Urol. 2019 Jan;75(1):100-110. doi: 10.1016/j.eururo.2018.10.010. Epub 2018 Oct 13.
4
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Eur Urol. 2021 Mar;79(3):339-342. doi: 10.1016/j.eururo.2020.12.005. Epub 2020 Dec 24.
5
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations.
BMC Urol. 2020 Jul 2;20(1):84. doi: 10.1186/s12894-020-00647-w.
6
The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Eur Urol. 2021 Oct;80(4):393-397. doi: 10.1016/j.eururo.2021.04.042. Epub 2021 May 29.
7
Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Missed Opportunity.
Clin Genitourin Cancer. 2022 Apr;20(2):e158-e165. doi: 10.1016/j.clgc.2021.12.002. Epub 2021 Dec 10.
8
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21.
9
Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
Curr Treat Options Oncol. 2022 Apr;23(4):609-629. doi: 10.1007/s11864-022-00966-0. Epub 2022 Mar 22.
10
Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.
J Exp Clin Cancer Res. 2021 Jun 7;40(1):186. doi: 10.1186/s13046-021-01961-3.
引用本文的文献
1
Overexpression of mG writers METTL1 and BUD23 confers oncogenicity in kidney renal clear cell carcinoma.
J Pathol. 2025 Sep;267(1):1-9. doi: 10.1002/path.6453. Epub 2025 Jul 18.
2
Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance.
Sci Rep. 2025 Jun 5;15(1):19818. doi: 10.1038/s41598-025-04917-1.
3
Hyperprogressive Disease In a Metastatic Renal Cell Carcinoma Patient After Receiving Immune Checkpoint Inhibitors: A Case Report.
Cureus. 2022 Oct 11;14(10):e30194. doi: 10.7759/cureus.30194. eCollection 2022 Oct.
4
The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis.
Cancers (Basel). 2022 Oct 26;14(21):5258. doi: 10.3390/cancers14215258.
5
Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.
Front Immunol. 2022 Aug 19;13:954440. doi: 10.3389/fimmu.2022.954440. eCollection 2022.
6
Decoding the Immune Microenvironment of Clear Cell Renal Cell Carcinoma by Single-Cell Profiling to Aid Immunotherapy.
Front Immunol. 2022 Jun 24;13:791158. doi: 10.3389/fimmu.2022.791158. eCollection 2022.
7
Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials.
Cancers (Basel). 2022 Jun 10;14(12):2867. doi: 10.3390/cancers14122867.
8
Alcohol and Head and Neck Cancer: Updates on the Role of Oxidative Stress, Genetic, Epigenetics, Oral Microbiota, Antioxidants, and Alkylating Agents.
Antioxidants (Basel). 2022 Jan 11;11(1):145. doi: 10.3390/antiox11010145.
9
Prognostic Value of Long Noncoding RNA DLEU2 and Its Relationship with Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma.
Int J Gen Med. 2021 Nov 11;14:8047-8064. doi: 10.2147/IJGM.S336428. eCollection 2021.
本文引用的文献
1
Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.
J Clin Oncol. 2022 Jul 1;40(19):2128-2137. doi: 10.1200/JCO.21.02631. Epub 2022 Mar 11.
2
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982.
3
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
4
Cancer Statistics, 2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
5
Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer.
Cancers (Basel). 2020 Nov 30;12(12):3574. doi: 10.3390/cancers12123574.
6
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
J Clin Oncol. 2020 Sep 20;38(27):3088-3094. doi: 10.1200/JCO.19.03315. Epub 2020 Jun 3.
7
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.
JAMA Oncol. 2020 Oct 1;6(10):1606-1610. doi: 10.1001/jamaoncol.2020.2169.
8
Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma.
Clin Cancer Res. 2020 May 15;26(10):2327-2336. doi: 10.1158/1078-0432.CCR-19-2427. Epub 2020 Feb 7.
9
Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma.
Cancer Discov. 2019 Oct;9(10):1349-1357. doi: 10.1158/2159-8290.CD-19-0499. Epub 2019 Sep 16.
10
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
Zotero 插件